摘要
替格瑞洛是一个起效迅速、作用强效、与P2Y12受体可逆结合的抗血小板聚集药物。替格瑞洛不同于其他噻吩并吡啶类P2Y12受体拮抗剂的临床获益,与P2Y12受体拮抗以外的作用密切相关。近来研究发现,替格瑞洛可以通过抑制腺苷转运体ENT1,特别是在缺血和组织损伤处,提高血浆中腺苷的浓度,增加腺苷介导的生物学效应。本文将对替格瑞洛增加腺苷介导的生物学效应作一综述。
Summary Ticagrelor is an effective and reversible inhibitor of platelet aggregation. Differing from thienopyr idine P2Y12 antagonists, the clinical benefits and adverse effects of ticagrelor are closely related to its additional effects. Recent researches found that it provided protection against ischemic injury via inhibition of adenosine transporter, increasing adenosine concentration and enhancemant the biological activity of adenosine. This review is going to summarize the biological effects of ticagrelor as a result of its role in increasing adenosine plasma concentrations.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2015年第2期122-124,共3页
Journal of Clinical Cardiology
